Racial differences in fibrosis progression after HCV-related liver transplantation Journal Article

Local Library Link: Find It @ Loyola

Authors: Layden, J. E.; Cotler, S; Brown, K. A.; Lucey, M. R.; Te, H. S.; Eswaran, S.; Fimmel, C.; Layden, T. J.; Clark, N. M.
Article Title: Racial differences in fibrosis progression after HCV-related liver transplantation
Abstract: BACKGROUND: Black recipients undergoing liver transplantation (LT) for hepatitis C virus (HCV) have decreased patient and graft survival compared with white recipients, a finding that is primarily limited to black recipients of livers from white donors. The cause(s) for these discrepant outcomes are unclear but may be related to HCV disease recurrence. The rates of HCV-related disease recurrence and liver fibrosis progression among black and white liver transplant recipients have not been investigated. METHODS: In this study, we compared liver fibrosis progression between 105 black and 364 white recipients after HCV-related LT in a multisite cohort study and assessed the impact of donor race. RESULTS: At 6, 12, and 24 months after LT, there was a significantly higher percentage in the black recipient/white donor (B/W) group with severe fibrosis, defined as stage 3 or 4 (F3/F4), compared with all other recipient/donor race combinations. The adjusted odds ratio of developing F3/F4 for the B/W group was 2.54 (1.49-4.69; reference group, white recipient/white donor). Black recipients with black donors demonstrated a similar rate of progression to F3/F4 as white recipients. Patient survival was also decreased in the B/W group compared with other recipient/donor race combinations. CONCLUSION: African American recipients with white donors have more severe fibrosis progression after HCV-related LT. The mechanisms responsible for accelerating fibrosis progression in this high-risk race-mismatched group need to be investigated.
Journal Title: Transplantation
Volume: 94
Issue: 2
ISSN: 1534-6080; 0041-1337
Publisher: Unknown  
Journal Place: United States
Date Published: 2012
Start Page: 178
End Page: 184
Language: eng
DOI/URL:

10.1097/TP.0b013e318253f7fa

10.1097/TP.0b013e318253f7fa
Notes: ID: 12854; LR: 20130415; GR: KL2 RR029878/RR/NCRR NIH HHS/United States; GR: KL2RR029878/RR/NCRR NIH HHS/United States; GR: L30 DK089908/DK/NIDDK NIH HHS/United States; GR: UL1 RR029879/RR/NCRR NIH HHS/United States; JID: 0132144; NIHMS454023; OID: NLM: NIHMS454023; OID: NLM: PMC3624617; ppublish